Lyra Therapeutics (NASDAQ:LYRA) saw its stock soar by 180% after releasing encouraging Phase 3 results for its lead ...

Most CRS, ICANS, and neuro events after liso-cel were mild and occurred within 15 days post-infusion, according to different ...

It made me feel good, of course, to be associated with the project that was where children weren’t dying,” said CRS’ Bill ...

Tennis anyone? How about pickleball? Just in time for summer, the new tennis and pickleball courts behind Avon Lake High ...

The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Kabankalan City in Negros Occidental is set to host the first local government-managed Civil Registry System (CRS) outlet in ...

NHTSA Seeks Fix to Child Safety Restraint Standard Affecting School Buses School Transportation News Special Reports ...

President Trump’s fiery breakup with former adviser Elon Musk quickly escalated Thursday as the commander in chief floated ...

The interim data, with a cutoff date of April 11, 2025, showed an impressive 70% CR rate. Prior to NXC-201 treatment, the ...